Fecal Microbiota Transplantation in Patients With Cirrhosis: A Systematic Review and Meta-Analysis of Efficacy and Safety

INTRODUCTION: Cirrhosis constitutes a major burden, owing to frequent decompensations, rehospitalizations, and significant clinical implications. Current standard, symptom-targeted therapies are limited in effectiveness. Targeting the gut-liver axis as the upstream driver of decompensation, fecal microbiota transplantation (FMT) may be beneficial. METHODS: Following PRISMA, we searched Scopus, ScienceDirect, PubMed, Cochrane, Embase, and ClinicalTrials.gov for studies investigating FMT for cirrhosis. Quality of randomized trials was evaluated using the Cochrane Risk-of-Bias (RoB) 2.0, nonrandomized studies using Risk Of Bias In Nonrandomised Studies-of Interventions (ROBINS-I), and case series using the Joanna Briggs Institute tool. Inverse-variance random-effects models were fitted in R 4.5.2, with between-study variance estimated by restricted maximum likelihood. Pooled risk ratios (RR) were derived from participant-level event counts for binary outcomes and Hartung-Knapp adjusted standardised mean differences (SMD) for continuous outcomes. Certainty of evidence was rated using GRADE. RESULTS: Nine studies with 245 participants were included; 4 contributed to the quantitative synthesis. FMT reduced hepatic encephalopathy (HE) recurrence (4 comparisons, 80 participants, 16 events; RR=0.22 [95% CI: 0.08-0.62]; P=0.0040; I²=0%) and liver-related hospitalisation [4 comparisons, 80 participants, 19 events; RR=0.29 (95% CI: 0.12-0.69); P=0.0050; I²=0%], although the hospitalisation effect was not retained when all-cause admissions were analysed [RR=0.69 (95% CI: 0.35-1.36); P=0.28]. Serious adverse events were borderline lower with FMT [5 comparisons, 100 participants, 42 events; RR=0.54 (95% CI: 0.29-0.99); P=0.0461; I²=13.2%], but this estimate was not robust to leave-one-out analysis. Only one serious event across all 9 studies was adjudicated as FMT-attributable. FMT did not significantly change MELD scores [SMD= -0.12 (95% CI: -0.48 to 0.24)] or serum ammonia [SMD= -0.27 (95% CI: -0.67 to 0.12)]. Certainty of evidence was low for HE recurrence and very low for all other outcomes. CONCLUSION: Low-certainty evidence from 4 small trials suggests that FMT may reduce HE recurrence in cirrhosis, with no signal of excess treatment-related harm. The evidence base is still limited, and future adequately powered randomised trials are still required to compare routes of administration, or to support a change in practice.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Gastroenterology
Published
2026-11-18
DOI
https://doi.org/10.1097/mcg.0000000000002470
Primary Topic
Liver Disease and Transplantation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Fecal Microbiota Transplantation in Patients With Cirrhosis: A Systematic Review and Meta-Analysis of Efficacy and Safety

Kristie Huirong Fan, Rino Alvani Gani, Valerie Josephine Dirjayanto, Refael Alfa Budiman et al.
3 links
Journal of Clinical Gastroenterology
Liver Disease and Transplantation
article

Fecal Microbiota Transplantation in Patients With Cirrhosis: A Systematic Review and Meta-Analysis of Efficacy and Safety

Kristie Huirong Fan, Rino Alvani Gani, Valerie Josephine Dirjayanto, Refael Alfa Budiman, Pitt Akbar
article en

Abstract

INTRODUCTION: Cirrhosis constitutes a major burden, owing to frequent decompensations, rehospitalizations, and significant clinical implications. Current standard, symptom-targeted therapies are limited in effectiveness. Targeting the gut-liver axis as the upstream driver of decompensation, fecal microbiota transplantation (FMT) may be beneficial. METHODS: Following PRISMA, we searched Scopus, ScienceDirect, PubMed, Cochrane, Embase, and ClinicalTrials.gov for studies investigating FMT for cirrhosis. Quality of randomized trials was evaluated using the Cochrane Risk-of-Bias (RoB) 2.0, nonrandomized studies using Risk Of Bias In Nonrandomised Studies-of Interventions (ROBINS-I), and case series using the Joanna Briggs Institute tool. Inverse-variance random-effects models were fitted in R 4.5.2, with between-study variance estimated by restricted maximum likelihood. Pooled risk ratios (RR) were derived from participant-level event counts for binary outcomes and Hartung-Knapp adjusted standardised mean differences (SMD) for continuous outcomes. Certainty of evidence was rated using GRADE. RESULTS: Nine studies with 245 participants were included; 4 contributed to the quantitative synthesis. FMT reduced hepatic encephalopathy (HE) recurrence (4 comparisons, 80 participants, 16 events; RR=0.22 [95% CI: 0.08-0.62]; P=0.0040; I²=0%) and liver-related hospitalisation [4 comparisons, 80 participants, 19 events; RR=0.29 (95% CI: 0.12-0.69); P=0.0050; I²=0%], although the hospitalisation effect was not retained when all-cause admissions were analysed [RR=0.69 (95% CI: 0.35-1.36); P=0.28]. Serious adverse events were borderline lower with FMT [5 comparisons, 100 participants, 42 events; RR=0.54 (95% CI: 0.29-0.99); P=0.0461; I²=13.2%], but this estimate was not robust to leave-one-out analysis. Only one serious event across all 9 studies was adjudicated as FMT-attributable. FMT did not significantly change MELD scores [SMD= -0.12 (95% CI: -0.48 to 0.24)] or serum ammonia [SMD= -0.27 (95% CI: -0.67 to 0.12)]. Certainty of evidence was low for HE recurrence and very low for all other outcomes. CONCLUSION: Low-certainty evidence from 4 small trials suggests that FMT may reduce HE recurrence in cirrhosis, with no signal of excess treatment-related harm. The evidence base is still limited, and future adequately powered randomised trials are still required to compare routes of administration, or to support a change in practice.

Journal of Clinical Gastroenterology
National University of Singapore (SG), University of Indonesia (ID), National University Hospital (SG), National University Health System (SG), Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo (ID)
Good health and well-being
Liver Disease and Transplantation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon